Skp2 contains a novel cyclin A binding domain that directly protects cyclin A from inhibition by p27Kip1
Peng Ji1, Luba Goldin, Hao Ren
1Department of Developmental and Molecular Biology, the Albert Einstein Comprehensive Cancer Center and Liver Research Center, Albert Einstein College of Medicine, Bronx, New York 10461, USA.
Abstract:
Skp2 is well known as the F-box protein of the SCF(Skp2) x Roc1 complex targeting p27 for ubiquitylation. Skp2 also forms complexes with cyclin A, which is particularly abundant in cancer cells due to frequent Skp2 overexpression, but the mechanism and significance of this interaction remain unknown. Here, we report that Skp2-cyclin A interaction is mediated by novel interaction sequences on both Skp2 and cyclin A, distinguishing it from the well known RXL-hydrophobic patch interaction between cyclins and cyclin-binding proteins. Furthermore, a short peptide derived from the mapped cyclin A binding sequences of Skp2 can block Skp2-cyclin A interaction but not p27-cyclin A interaction, whereas a previously identified RXL peptide can block p27-cyclin A interaction but not Skp2-cyclin A interaction. Functionally, Skp2-cyclin A interaction is separable from Skp2 ability to mediate p27 ubiquitylation. Rather, Skp2-cyclin A interaction serves to directly protect cyclin A-Cdk2 from inhibition by p27 through competitive binding. Finally, we show that disruption of cyclin A binding with point mutations in the cyclin A binding domain of Skp2 compromises the ability of overexpressed Skp2 to counter cell cycle arrest by a p53/p21-mediated cell cycle checkpoint without affecting its ability to cause degradation of cellular p27 and p21. These findings reveal a new functional mechanism of Skp2 and a new regulatory mechanism of cyclin A.
Insights
Skp2 (Skip complex-associated protein 2) interacts with cyclin A via novel sequences, distinct from its role in p27 degradation. This interaction protects cyclin A-Cdk2 from p27 inhibition, impacting cell cycle checkpoints.
Area of Science:
- Cell Biology
- Molecular Biology
- Cancer Research
Background:
- Skp2 (Skip complex-associated protein 2) is an F-box protein known for targeting p27 for ubiquitylation.
- Skp2 overexpression is common in cancer, and its interaction with cyclin A is observed but mechanistically unclear.
Purpose of the Study:
- To elucidate the mechanism and functional significance of the Skp2-cyclin A interaction.
- To determine if this interaction is distinct from Skp2's role in p27 ubiquitylation and its impact on cell cycle regulation.
Main Methods:
- Peptide competition assays to differentiate binding interactions.
- Site-directed mutagenesis to disrupt Skp2-cyclin A binding.
- Analysis of cell cycle progression and protein degradation pathways.
Main Results:
- Skp2-cyclin A interaction is mediated by novel sequences, separate from the RXL-hydrophobic patch interaction critical for p27 binding.
- Skp2-cyclin A interaction protects cyclin A-Cdk2 from p27-mediated inhibition.
- Disrupting Skp2-cyclin A binding impairs Skp2's ability to overcome p53/p21-induced cell cycle arrest.
Conclusions:
- Skp2 possesses a novel function in directly regulating cyclin A activity through competitive binding with p27.
- This Skp2-cyclin A interaction plays a significant role in cell cycle control, independent of Skp2's canonical role in p27 degradation.
Related Concept Videos
Inhibition of Cdk Activity
Inhibition of CDK Activity
Positive Regulator Molecules
Positive Regulator Molecules
Anaphase Promoting Complex
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...


